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Background: Cystic fibrosis related diabetes (CFRD) with fasting hyperglycemia is found in 15% of adult and 11% of adolescent CF patients.
Because of concerns about hypoglycemia, it is not common practice to treat CFRD with 24-hour basal insulin therapy, despite evidence that
insulin deficiency may contribute to protein catabolism and have an adverse effect on weight, muscle mass, pulmonary function, and,
ultimately, survival. We hypothesized that insulin glargine would improve blood glucose control and weight in patients with CFRD without
causing hypoglycemia.
Methods: A randomized cross-over study compared 12 weeks each of bedtime NPH or glargine in 19 CFRD patients.
Results: There was significantly greater reduction in fasting plasma glucose with glargine (P=0.03), and participants showed a non-
significant trend towards weight gain with this insulin (P=0.07). No serious hypoglycemia occurred. At study end, all patients chose to
continue glargine.
Conclusions: A study of longer duration is needed to determine whether insulin glargine impacts protein catabolism and overall clinical status
in CF patients, but these initial data suggest that this is a promising therapy in CFRD.
© 2007 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; CFRD; Glargine1. Background
Cystic fibrosis related diabetes (CFRD) with fasting
hyperglycemia occurs in about 15% of adult and 11% of
adolescent patients [1,2]. They are partially insulin deficient
due to fibrotic pancreas damage, but enough endogenous
insulin is generally present to prevent ketosis. Standard in-
sulin therapy has focused on meal coverage; basal insulin is
typically only provided overnight in the form of NPH [3].
Daytime basal insulin therapy is not usually prescribed based
on the historical observation that most of these patients,
unless they are acutely ill, are able to maintain normal blood
glucose levels during the day as long as rapid-acting insulin
is given with meals. In addition, daytime NPH may result in⁎ Corresponding author. Pediatric Endocrinology MMC 404, University
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fluctuating health status leads to unpredictable food intake
and activity. We hypothesized that insulin glargine would
improve blood glucose control and weight in patients with
CFRD without causing hypoglycemia.
2. Methods
Twenty adult patients with CFRD with FH were recruited.
All were clinically well and receiving a single dose of bed-
time NPH insulin plus rapid-acting insulin 3–6 times per day
before meals.
Twelve week therapy with bedtime NPH was compared
to 12 weeks of bedtime glargine in a randomized cross-
over study. Before each study period there was a 1-month
insulin adjustment period. Target glucose goals were 80–
120 mg/dl fasting and 80–150 mg/dl 2 h after meals. Insulin
aspart was given pre-meal at least 3×/day according to the
patient's individually established insulin:carbohydrate ratioed by Elsevier B.V. All rights reserved.
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study nurse every 1–2 weeks for insulin adjustment.
Patients were seen in the GCRC at 0, 6 and 12 weeks,
with time 0 starting at the end of the insulin adjustment
month. Average fasting and 2 hr post-dinner glucose levels
by meter were calculated. Records and patient history were
evaluated for hypoglycemia. Dual energy X-ray absorptio-
metry was employed to assess body composition.
Demographic characteristics of the two sequence groups
(NPH–glargine and glargine–NPH) were compared using
two-sample t-tests; gender proportions were compared using a
chi-square test. Two models were fitted for each outcome, the
first adjusting for period effect alone and the second adjusting
for both period and baseline value, using a repeated-measures
analysis of variance which included a test for differences
between the sequence groups, that is, an interaction between
sequence and treatment. Standard deviations of individual
patient glucose monitor records were calculated from first
differences (differences between consecutive records) to eli-
minate the effect of changes in the mean over time. Means are
reported±standard error of the mean.
3. Results
Twenty subjects enrolled; one dropped out. There were 9
men and 10 women, age 34±8 yr with BMI 22.4±2.8 kg/m2.
Duration of diabetes was 9±5 yr and diabetes was well
controlled (baseline HbA1c 6.5±0.1%). The group which
received NPH first (n=9) was similar in demographic
characteristics and gender proportion to the group which
received glargine first.
There was no indication of an interaction between
sequence (NPH–glargine, glargine–NPH) on outcome.
Table 1 shows changes in study endpoints. Baseline values
were associated with mean change in outcome and were used
to adjust estimated mean changes. There was significantly
greater reduction in fasting plasma glucose during glargine
treatment (P=0.03), but no differences in HbA1c or post-Table 1
Changes in study outcomes from baseline (the end of the 1-month insulin-
adjustment phase of each arm) to week 12, adjusted for the baseline value of
the outcome (presented in parentheses)
Glargine NPH P
Hemoglobin A1c , % − 0.2±0.1 − 0.2±0.1 .96
(6.4±0.2) (6.6±0.2)
Fasting plasma glucose, mg/dl − 8±2 − 0±2 .03
(123±4) (125±5)
2 h postprandial glucose, mg/dl − 6±5 − 8±5 .85
(150±6) (155±9)
Weight, kg + 1.2±0.5 + 0.2±0.5 .07
(64.3±2.4) (65.7±2.5)
Fat mass by DEXA, kg + 0.7±0.4 + 0.4±0.4 .09
(16.1±1.4) (16.7±1.5)
Lean mass by DEXA, kg + 0.3±0.2 + 0.1±0.2 .50
(45.7±1.9) (45.7±2.0)
Values are mean±SEM, with negative changes indicating a decrease and
positive changes an increase.prandial plasma glucose. Participants tended to gain more
weight on glargine (P=0.07), but this was not significant and
body composition was unchanged.
The average total daily insulin dose was 0.7 units/kg/
day for each insulin. The insulin:carbohydrate ratios were
1.5±0.2 (NPH) and 1.3±0.1 (glargine) units insulin aspart/
15 g carbohydrate, P=0.05. Glargine was 46±4% and
NPH 38±3% of the total daily insulin dose.
No difference in quality of life was seen. After the study
was complete, all 19 patients chose to continue glargine
therapy. The most common reason stated was that daytime
blood glucose levels seemed more consistent. In addition,
some patients were less worried about nighttime hypoglyce-
mia. Despite patient perception, variability in glucose levels
appeared to be similar between the treatment arms. The
within-patient standard deviation of fasting glucose levels
(NPH: 50±10 mg/dl, glargine: 40±6 mg/dl, P=0.18) and
2 h post-prandial glucose levels (NPH: 91±7 mg/dl, glargine:
83±6 mg/dl, P=0.28) was not significantly different.
There was no difference in adverse events between study
arms. No serious hypoglycemia occurred. Minor hypogly-
cemic episodes occurred 6±1 times per participant in the
glargine arm and 5±1 times in the NPH arm, P=0.3.
4. Conclusions
We found significantly greater reduction in fasting plasma
glucose with glargine compared to NPH in CF. Participants
showed a non-significant tendency to gain weight, which we
speculate might be related to the anabolic effect of con-
tinuous basal insulin coverage. These advantages were ac-
complished without an increase in the number or severity of
hypoglycemic events. Glargine was well accepted by
patients, each whom chose to remain on it at study end.
The standard practice of omitting daytime basal insulin in
CFRD, based on practical considerations, ignores the rela-
tionship between insulin deficiency and clinical decline.
Pulmonary function deteriorates more rapidly in CF patients
with diabetes, and the annual rate of decline in lung function
is directly related to the severity of insulin deficiency [4].
Mortality is greater in CF patients who have diabetes com-
pared to those who do not [5,6]. Survival in CF is well
known to be dependent on good nutritional status, and in-
sulin is a potent anabolic agent. Excessive protein catabolism
[7,8] and lipolysis [9] are seen even in clinically stable CF
patients with abnormal glucose tolerance, and the resulting
loss of weight and lean body mass may contribute to pul-
monary disease and clinical decline. Thus, insulin replace-
ment for anabolic purposes may be more important in CFRD
than control of hyperglycemia.
The current study is limited by its relatively short dura-
tion, since the results might not have been sustained over a
longer period. Also, there was no practical way to blind the
study, and patients might have perceived an advantage
because glargine was newer or they may have been influenced
by the healthcare team. Weight changes did not achieve
136 P. Grover et al. / Journal of Cystic Fibrosis 7 (2008) 134–136statistical significance. Longterm studies are needed to deter-
mine the metabolic and nutritional impact of glargine in
CFRD, but these initial data suggest that this is a promising
therapy in CFRD.
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